Document is current
Any future updates will be listed below
-
Authors
Su, Pei https://orcid.org/0000-0001-6148-0181
Hollas, Michael A. R. https://orcid.org/0000-0002-0797-3134
Pla, Indira
Rubakhin, Stanislav https://orcid.org/0000-0003-0437-1493
Butun, Fatma Ayaloglu
Greer, Joseph B.
Early, Bryan P.
Fellers, Ryan T.
Caldwell, Michael A. https://orcid.org/0000-0002-8636-0706
Sweedler, Jonathan V. https://orcid.org/0000-0003-3107-9922
Kafader, Jared O.
Kelleher, Neil L. https://orcid.org/0000-0002-8815-3372
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (P41 GM108569)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (UH3 CA246635)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (P30 DA018310, P30 CA060553)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (K99 AI183290)
- License Information
-
More Information
Article History
Received: 3 July 2023
Accepted: 4 April 2025
First Online: 15 May 2025
Competing interests
: J.O.K. and N.L.K. report a conflict of interest with I2MS technology, being commercialized by Thermo Fisher Scientific. R.T.F., J.B.G. and N.L.K. are involved in commercialization of software. N.L.K. is a paid consultant for Thermo Fisher Scientific. The other authors declare no competing interests.
